Table 2.
Percentage change in CTX and P1NP levels from baseline (AECOPD) to 1- and 3-month follow-up
| Total N = 318 | Baseline (μg/L) N = 298 |
1 month (difference from baseline (95% CI)) N = 213 |
3 months (difference from baseline (95% CI)) N = 193 |
|---|---|---|---|
|
CTX Low-dose group |
196 | −20% (− 30, − 8%); p < 0.0013 | − 4% (− 17, 10%); p = 0.55 |
|
CTX High-dose group |
196 | −26% (− 35, − 16%); p < 0.0001 | −23% (− 32, − 12%); p = 0.0001 |
| Relative difference between treatment groupsa | 9% (−8, 28%); p = 0.33 | 24% (4, 49%); p = 0.017 | |
|
P1NP Low-dose group |
34 | 60% (47, 75%); p < 0.0001 | 53% (38, 69%); p < 0.0001 |
|
P1NP High-dose group |
34 | 64% (51, 78%); p < 0.0001 | 63% (49, 79%); p < 0.0001 |
| Relative difference between treatment groupsa | −2% (− 14, 10%); p = 0.70 | −6% (− 18, 7%); p = 0.33 | |
|
P1NP/CTX ratio Low dose group |
0.11 | 2.18 (1.91–2.49) p < 0.0001 | 2.11 (1.82; 2.40) p < 0.0001 |
|
P1NP/CTX ratio High dose group |
0.11 | 2.08 (1.81;2.39) p < 0.0001 | 1.70 (1.46; 1.97) p < 0.0001 |
| Relative difference between treatment groupsa | 0.95 (0.81; 1.12) p = 0.56 | 0.81 (0.67; 0.98) p = 0.029 |
athe relative difference between groups is calculated as the time–group interaction at the specific visit
Abbreviations: CTX C-terminal telopeptide of type 1 collagen, P1NP procollagen type 1 N-terminal propeptide